近年来出现的聚腺苷二磷酸核糖聚合酶 [poly(ADP-ribose)polymerase,PARP] 抑制剂(PARP inhibitor,PARPi)为新型的靶向治疗药物之一,已经被应用于治疗包括乳腺癌在内的多种恶性肿瘤,并且已获得许多显著的效果,成为相关肿瘤研究的热点之一。 PARPi 的上市状况 PARPi 主要分为...
[19] Isakoff S J, Overmoyer B, Tung N M, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer [J]. J Clin Oncol, 2010, 28(15s): 1019. 作者:春风健康海外就医购药服务机构总编 - 卑弥呼 ...
通过抑制DNA修复产生DNA损伤,增加肿瘤突变负荷,成为更具识别性的免疫治疗靶点。 《TherapeuticPotential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors》刊登于Frontiers in Oncology肿瘤学前沿杂志中,详述阐明了PARP抑制和免疫联...
参考文献: [1] Pham M M , Ngoi N , Peng G , et al. Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises[J]. Trends in Cancer, 2021. [2] Vikas P, Borcherding N, Chennamadhavuni A, Garje R. Therapeutic Potential of Comb...
《TherapeuticPotential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors》刊登于Frontiers in Oncology肿瘤学前沿杂志中,详述阐明了PARP抑制和免疫联合治疗在改善实体肿瘤患者预后方面的前景,总结早期研究成果并展望进行中的研究,下面就由小编来为大家解读一下这篇文章。
[2] AstraZeneca eyes a safer PARP inhibitor, with nearly 50% response in advanced breast cancer patients: #AACR24. Retrieved April 8, 2024, from https://endpts.com/astrazeneca-eyes-a-safer-parp-inhibitor-with-nearly-50-response-in-advanced-breast-cancer-patients-aacr24/ ...
Wider access to testing for BRCA and other mutations, and to genetic counseling, are required to identify patients who could benefit from PARP inhibitor therapy. The advent of PARP inhibitors has potential benefits for BC treatment beyond the locally advanced/metastatic setting....
[2] AstraZeneca eyes a safer PARP inhibitor, with nearly 50% response in advanced breast cancer patients: #AACR24. Retrieved April 8, 2024, from https://endpts.com/astrazeneca-eyes-a-safer-parp-inhibitor-with-nearly-50-response-in-advanced-breast-cancer-patients-aacr24/...
“Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.” Gynecologic oncology vol. 166,1 (2022): 117-125.doi:10.1016/j.ygyno....
Areas covered: Promising results have been achieved with PARP inhibitors in BRCA associated cancers, particularly in ovarian and breast cancer. Olaparib is the only PARP inhibitor approved by FDA in the treatment of patients with germline BRCA mutated advanced ovarian cancer pretreated with ≥3 prior...